BICALUTAMIDE TEVA 150 mg
 |
|
|
Package:
TABLETS: 30.
Dosage:
The tablets should not be chewed or crushed. The tablets should not be divided since there is no score line.
Adult males including the elderly: 1 tablet (150 mg) orally 1 x daily.
Should be taken continuously for at least 2 years or until disease progression.
Renal impairment: No dosage adjustment is necessary.
Hepatic impairment: No dosage adjustment is necessary for patients with mild hepatic impairment. Increased accumulation may occur in patients with moderate to severe hepatic impairment.
Prescribing Restrictions:
Indications:
In patients with locally advanced prostate cancer (T3-T4, any N, M0; T1-T2, N+, M0), as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy.
For the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.
Contra-Indications:
Females and children. Must not be given to any patient who has shown a hypersensitivity to the active substance or any of the excipients. Co-administration of terfenadine, astemizole or cisapride is contraindicated.
Special Precautions:
See literature. Please contact distributor for full information.
Side Effects:
See literature. Please contact distributor for full information.
Drug Interactions:
See literature. Please contact distributor for full information.
